CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 205 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Escitalopram 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00894543
NCT00894543N/ACompleted
CompareCT.gov

Menopause Strategies: Finding Lasting Answers for Symptoms and Health: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women

Fred Hutchinson Cancer Center·interventional·Posted May 7, 2009·Updated Mar 8, 2013

In Brief

A clinical study evaluating Escitalopram and Placebo for Hot Flashes and 2 related conditions. Completed, enrolled 205 participants across 5 sites.

Detailed Summary

The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro®) is a selective serotonin reuptake inhibitor (SSRI). It is sold by prescription for depression and general anxiety disorder. An SSRI increases serotonin, a brain substance that is believed to influence mood. Serotonin may also affect brain levels of estradiol, a hormone related to hot flashes. This research study will test whether escitalopram reduces menopausal hot flashes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHot Flashes, Menopause, Vasomotor Symptoms
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH), Office of Research on Women's Health (ORWH)

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 7, 2009
Enrollment StartJul 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.2 years ago

Interventions

Escitalopramdrug

10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.

Placeboother

Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.